MR Antagonist and LSD1

Description

Lysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investigates whether a genetically driven anti-hypertensive approach proves superior in controlling blood pressure and mitigating renal injury in Blacks who carry the risk allele for LSD1 (rs587168). The findings of these investigations may lead to a new approach in treating a subset (\~30%) of the essential hypertension population (Black LSD1 risk allele hypertensives).

Conditions

Hypertension, Mineralocorticoid Excess

Study Overview

Study Details

Study overview

Lysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investigates whether a genetically driven anti-hypertensive approach proves superior in controlling blood pressure and mitigating renal injury in Blacks who carry the risk allele for LSD1 (rs587168). The findings of these investigations may lead to a new approach in treating a subset (\~30%) of the essential hypertension population (Black LSD1 risk allele hypertensives).

Role of LSD1 in Hypertension in Blacks

MR Antagonist and LSD1

Condition
Hypertension
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women's, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * untreated as well as currently treated hypertensives
  • * rs587168 allele carriers
  • * not on more than two anti-hypertensives
  • * normal renal, metabolic, electrolyte, and CBC laboratory tests
  • * self-identified Black race
  • * age \>17 yrs.
  • * known cardiac disease other than HTN
  • * renal, circulatory or neurologic diseases
  • * diabetes
  • * smoking
  • * secondary HTN as indicated by history, physical examination or screening blood and urine tests
  • * smoking
  • * any drug therapy, except for anti-hypertensives and stable thyroid medication replacement

Ages Eligible for Study

17 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Brigham and Women's Hospital,

Andrea Haas, MD, PRINCIPAL_INVESTIGATOR, Brigham and Women's

Study Record Dates

2026-06